Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Diazoxide-resistant hyperinsulism (DRH) is form of congenital isolated hyperinsulinism caused by an abnormal insulin production by b-cells in the pancreas that can be diffuse or focal and is characterized by an excessive/ uncontrolled insulin secretion (inappropriate for the level of glycemia), recurrent episodes of profound hypoglycemia and resistance to medical management with diazoxide
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia.
2 publications have been identified in PubMed for adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia. Research spans Review / Meta-Analysis (50%) and Case Report / Case Series (50%).
Abdul-Hafez HA (2025). [PMID: 40337412](https://pubmed.ncbi.nlm.nih.gov/40337412/). *Ann Med Surg (Lond)*. [Case Report / Case Series]
Larsen AR (2024). [PMID: 38305063](https://pubmed.ncbi.nlm.nih.gov/38305063/). *Histol Histopathol*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Oct 4, 2026, 6:18 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia